What are the recommended treatment options and prognosis for erythema nodosum leprosum in an adult with multibacillary leprosy presenting with painful nodular skin lesions, fever, and possible neuritis?

Treatment of Erythema Nodosum Leprosum

For erythema nodosum leprosum (ENL), initiate high-dose corticosteroids as first-line therapy for acute episodes, with thalidomide (100-400 mg/day) as the preferred steroid-sparing agent for recurrent or chronic cases, while continuing multidrug therapy (MDT) for the underlying leprosy without interruption 1, 2.

Treatment Algorithm

Acute ENL Episodes

• Start oral prednisone 40-60 mg daily as the anti-inflammatory of choice
• Continue the patient's standard WHO multibacillary MDT regimen (rifampin, dapsone, clofazimine) without interruption 3, 4
• Taper corticosteroids gradually over 12-24 weeks based on clinical response
• Monitor closely for neuritis development, which requires aggressive corticosteroid therapy to prevent permanent nerve damage

Recurrent or Chronic ENL (Steroid-Dependent Cases)

• Add thalidomide 100-400 mg daily when patients require prolonged corticosteroid therapy (>3 months) or experience recurrence during steroid taper 2, 5
• Thalidomide acts rapidly and allows corticosteroid dose reduction
• Patients with bacillary index ≤4.0 and acute (vs chronic) ENL presentation have better recovery rates with thalidomide 2
• Early institution of thalidomide induces faster remission and prevents ENL recurrence 2

Alternative Agents (When First-Line Options Fail or Are Contraindicated)

• Clofazimine (dose escalation to 300 mg daily): slower onset but useful for chronic cases
• Pentoxifylline: limited efficacy, slower action
• Methotrexate: emerging option for steroid-sparing effect 5

Critical Management Considerations

Thalidomide Use Requires Strict Protocols:

• Absolute contraindication in women of childbearing potential unless rigorous contraception counseling and monitoring are implemented 2
• Most common side effect is pedal edema (73.5% of patients) 2
• Neurotoxicity risk with prolonged use 1
• Can be safely administered in outpatient settings with proper counseling 2

Steroid-Dependent ENL:

• Occurs when symptoms flare every time corticosteroids are tapered 6
• May require prolonged high-dose corticosteroids with gradual taper over months
• Consider adding thalidomide or methotrexate early to facilitate steroid withdrawal

Necrotic ENL Variant:

• Rare, severe presentation mimicking vasculitis with ulceronecrotic lesions 6
• May show negative bacilloscopy and atypical histology in patients on repeated MDT cycles
• Requires high-dose corticosteroids; diagnosis based on clinicopathological correlation 6

Prognosis

Favorable Prognostic Factors:

• Bacillary index ≤4.0 (37% increase in recovery incidence) 2
• Acute vs chronic ENL presentation (twice the likelihood of recovery) 2
• Completed MDT vs ongoing MDT (2.5 times greater improvement) 2
• Early thalidomide institution 2

Expected Outcomes:

• With appropriate treatment, complete resolution of skin lesions and neurological recovery is achievable 3
• Among compliant patients on thalidomide, 66.7% improve, with 16.2% experiencing recurrence 2
• ENL is frequently recurrent and/or chronic, causing significant physical disability and economic impact 1

Common Pitfalls:

• Interrupting MDT during ENL episodes—never stop the underlying leprosy treatment 3, 4
• Inadequate corticosteroid dosing or too-rapid taper leading to rebound
• Delaying thalidomide in chronic/recurrent cases, resulting in prolonged corticosteroid exposure and complications
• Missing neuritis, which requires immediate aggressive treatment to prevent permanent neuropathy 4
• Overlooking pregnancy risk with thalidomide—mandatory contraception counseling 2

Long-term Monitoring:

• ENL can occur during or after MDT completion 5
• Ongoing surveillance essential for detecting relapse, reinfection, or new reaction episodes 5
• Hypertrophic scarring may occur after severe necrotic ENL 6